Coherus BioSciences Stock News

Coherus BioSciences, Inc. (NASDAQ:CHRS ) Q1 2022 Earnings Conference Call May 5, 2022 4:30 PM ET Company Participants McDavid Stilwell - CFO Denny Lanfear - President, CEO, and Chairman Paul Reider -

Coherus BioSciences (CHRS) delivered earnings and revenue surprises of -55% and 11.68%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

The FDA has issued a complete response letter (CRL) to Junshi Biosciences Co Ltd and Coherus BioSciences Inc's (NASDAQ: CHRS) toripalimab application for advanced recurrent or metastatic nasopha

REDWOOD CITY, Calif., April 29, 2022 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by Coherus BioSciences, Inc. (Nasdaq: CHRS), please note in the Conference Call Infor

REDWOOD CITY, Calif., April 29, 2022 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that its first quarter 2022 financial results will be released after

Coherus BioSciences (CHRS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Biotech stocks are very sensitive to some key catalysts such as the FDA decision date, aka PDUFA date, clinical readouts/presentations and Adcom meeting. The month of April will see some companies bel

Shanghai Junshi Biosciences Co Ltd and Coherus BioSciences Inc (NASDAQ: CHRS ) have shared biomarker analyses from the CHOICE-01 Phase 3 trial of toripalimab plus chemotherapy as first-line treatment of advanced squamous or non-squamous non-small cell lung cancer (NSCLC). As of October 31, 2021, at the final analysis, a significant improvement in … Full story available on Benzinga.com

Coherus BioSciences (CHRS) appointed Rosh Dias as chief medical officer ((CMO)).Dias joins Coherus most recently from Spruce Biosciences, where he was the CMO

Coherus BioSciences (CHRS) and partner Shanghai Junshi BioSciences said that their non-small cell lung cancer therapy toripalimab led to an improvement in progression-free survival.

REDWOOD CITY, Calif., March 04, 2022 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that senior management will present at the following investor confere

Coherus BioSciences (CHRS) and Shanghai Junshi Biosciences (SHJBF) esophageal cancer candidate toripalimab met co-primary endpoints in a phase 3 trial.

In last trading session, Coherus BioSciences Inc. (NASDAQ:CHRS) saw 0.65 million shares changing hands with its beta currently measuring 1.01. Company’s recent per share price level of $11.73 trading at $0.27 or 2.36% at ring of the bell on the day assigns it a market valuation of $939.46M. That closing price of CHRS’s stock is … Coherus BioSciences Inc. (NASDAQ:CHRS) Is 10.23% Above Its 52-Week Low, But How Long Will It Remain So? Read More »

Coherus BioSciences Inc''s (NASDAQ: CHRS ) Q4 net revenue was $73.4 million for Q4 FY21 compared to $110.4 million for the same period in 2020, missing estimates of $85.81 million. The decline was primarily due to a decrease in the number of units of Udenyca sold and a reduction in net realized price due to increased competition and COVID-19 impacts. The company posted an adjusted EPS … Full story available on Benzinga.com